http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2948400-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2604b2e5660da650ab5c7d7990459755 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 |
filingDate | 2015-05-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bccc4576cada269a98c2158e5ba23873 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df6895d01e9b594f1a2adbba95bd015e |
publicationDate | 2015-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2948400-A1 |
titleOfInvention | Treatment regimen tiacumicin compound |
abstract | A tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, and a pharmaceutical composition, containing a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a pharmaceutically acceptable solvate thereof, are provided for use in the oral treatment of Clostridium difficile infections (CDI) or Clostridium difficile associated diarrhea or disease (CD AD) in a patient in accordance with a dosage regimen selected from the group consisting of: i. Administering 200 mg of the tiacumicin compound BID for 5 days followed by 5 days of rest and then 200 mg once daily for a further 10 days and ii. Administering 200 mg of the tiacumicin compound BID for 5 days followed by a single 200 mg every other day for 20 days. Further, a method is provided for recovering of gut Bifidobacteria population in a patient, suffering from Clostridium difficile infections (CDI) or Clostridium difficile associated diarrhea or disease (CD AD) and receiving oral treatment with a tiacumicin compound, to 50 to 90 % of the gut Bifidobacteria population prior to administering the tiacumicin compound during days 15-45 after start of the treatment by orally administering the tiacumicin compound to the patient according to a dosage regimen, which is selected from the above-mentioned group. |
priorityDate | 2014-05-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 75.